{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T11:07:28Z","timestamp":1791976048257,"version":"4.4.0"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T00:00:00Z","timestamp":1763683200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T00:00:00Z","timestamp":1763683200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"This study was sponsored by Innogen Pharmaceutical Co. Ltd"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Diabetologia"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1007\/s00125-025-06593-2","type":"journal-article","created":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T21:44:27Z","timestamp":1763761467000},"page":"1494-1507","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Efficacy and safety of efsubaglutide alfa in individuals with type 2 diabetes (SUPER1): a randomised, double-blind, placebo-controlled, Phase IIb\/III trial"],"prefix":"10.1007","volume":"69","author":[{"given":"Dalong","family":"Zhu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianhua","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weimin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bimin","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaolin","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fang","family":"Bian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingju","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yihua","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chengyan","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xueying","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongwei","family":"Ling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoxia","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhifeng","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guoyue","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liping","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiuhai","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yibing","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weihong","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yawei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haifang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jifang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lili","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaokun","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyue","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keqin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongcai","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lili","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianrong","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shu","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haifeng","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chengxia","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Ni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lianshan","family":"Piao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongwei","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongyi","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yufeng","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanqing","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Mao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongqian","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianchao","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yangang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ning","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wuyan","family":"Pang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianxin","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yulong","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiming","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qinghua","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,21]]},"reference":[{"issue":"1","key":"6593_CR1","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1038\/s41392-024-01951-9","volume":"9","author":"X Lu","year":"2024","unstructured":"Lu X, Xie Q, Pan X et al (2024) Type 2 diabetes mellitus in adults: pathogenesis, prevention and therapy. Signal Transduct Target Ther 9(1):262. https:\/\/doi.org\/10.1038\/s41392-024-01951-9","journal-title":"Signal Transduct Target Ther"},{"issue":"10085","key":"6593_CR2","doi-asserted-by":"publisher","first-page":"2239","DOI":"10.1016\/S0140-6736(17)30058-2","volume":"389","author":"S Chatterjee","year":"2017","unstructured":"Chatterjee S, Khunti K, Davies MJ (2017) Type 2 diabetes. Lancet 389(10085):2239\u20132251. https:\/\/doi.org\/10.1016\/S0140-6736(17)30058-2","journal-title":"Lancet"},{"issue":"1","key":"6593_CR3","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/s2213-8587(21)00245-x","volume":"10","author":"A Ceriello","year":"2022","unstructured":"Ceriello A, Prattichizzo F, Phillip M, Hirsch IB, Mathieu C, Battelino T (2022) Glycaemic management in diabetes: old and new approaches. Lancet Diabetes Endocrinol 10(1):75\u201384. https:\/\/doi.org\/10.1016\/s2213-8587(21)00245-x","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"10322","key":"6593_CR4","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1016\/s0140-6736(21)01919-x","volume":"399","author":"I Lingvay","year":"2022","unstructured":"Lingvay I, Sumithran P, Cohen RV, le Roux CW (2022) Obesity management as a primary treatment goal for type 2 diabetes: time to reframe the conversation. Lancet 399(10322):394\u2013405. https:\/\/doi.org\/10.1016\/s0140-6736(21)01919-x","journal-title":"Lancet"},{"issue":"10","key":"6593_CR5","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1038\/s41569-023-00877-z","volume":"20","author":"ND Wong","year":"2023","unstructured":"Wong ND, Sattar N (2023) Cardiovascular risk in diabetes mellitus: epidemiology, assessment and prevention. Nat Rev Cardiol 20(10):685\u2013695. https:\/\/doi.org\/10.1038\/s41569-023-00877-z","journal-title":"Nat Rev Cardiol"},{"issue":"6","key":"6593_CR6","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/s2213-8587(20)30118-2","volume":"8","author":"V Srikanth","year":"2020","unstructured":"Srikanth V, Sinclair AJ, Hill-Briggs F, Moran C, Biessels GJ (2020) Type 2 diabetes and cognitive dysfunction-towards effective management of both comorbidities. Lancet Diabetes Endocrinol 8(6):535\u2013545. https:\/\/doi.org\/10.1016\/s2213-8587(20)30118-2","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"5","key":"6593_CR7","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1210\/endrev\/bnaa015","volume":"41","author":"IB Hirsch","year":"2020","unstructured":"Hirsch IB, Juneja R, Beals JM, Antalis CJ, Wright EE (2020) The evolution of insulin and how it informs therapy and treatment choices. Endocr Rev 41(5):733\u2013755. https:\/\/doi.org\/10.1210\/endrev\/bnaa015","journal-title":"Endocr Rev"},{"issue":"10","key":"6593_CR8","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1111\/j.1751-7176.2009.00063.x","volume":"11","author":"SI McFarlane","year":"2009","unstructured":"McFarlane SI (2009) Insulin therapy and type 2 diabetes: management of weight gain. J Clin Hypertens (Greenwich) 11(10):601\u2013607. https:\/\/doi.org\/10.1111\/j.1751-7176.2009.00063.x","journal-title":"J Clin Hypertens (Greenwich)"},{"issue":"5","key":"6593_CR9","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1007\/s00125-020-05366-3","volume":"64","author":"SA Amiel","year":"2021","unstructured":"Amiel SA (2021) The consequences of hypoglycaemia. Diabetologia 64(5):963\u2013970. https:\/\/doi.org\/10.1007\/s00125-020-05366-3","journal-title":"Diabetologia"},{"issue":"5","key":"6593_CR10","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1016\/S2213-8587(18)30315-2","volume":"7","author":"International Hypoglycaemia Study Group","year":"2019","unstructured":"International Hypoglycaemia Study Group (2019) Hypoglycaemia, cardiovascular disease, and mortality in diabetes: epidemiology, pathogenesis, and management. Lancet Diabetes Endocrinol 7(5):385\u2013396. https:\/\/doi.org\/10.1016\/S2213-8587(18)30315-2","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"2","key":"6593_CR11","doi-asserted-by":"publisher","first-page":"e175634","DOI":"10.1172\/jci175634","volume":"134","author":"DJ Drucker","year":"2024","unstructured":"Drucker DJ (2024) The GLP-1 journey: from discovery science to therapeutic impact. J Clin Invest 134(2):e175634. https:\/\/doi.org\/10.1172\/jci175634","journal-title":"J Clin Invest"},{"issue":"12","key":"6593_CR12","doi-asserted-by":"publisher","first-page":"4217","DOI":"10.1172\/jci97233","volume":"127","author":"DJ Drucker","year":"2017","unstructured":"Drucker DJ, Habener JF, Holst JJ (2017) Discovery, characterization, and clinical development of the glucagon-like peptides. J Clin Invest 127(12):4217\u20134227. https:\/\/doi.org\/10.1172\/jci97233","journal-title":"J Clin Invest"},{"issue":"19","key":"6593_CR13","doi-asserted-by":"publisher","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","volume":"375","author":"SP Marso","year":"2016","unstructured":"Marso SP, Bain SC, Consoli A et al (2016) Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med 375(19):1834\u20131844. https:\/\/doi.org\/10.1056\/NEJMoa1607141","journal-title":"N Engl J Med"},{"issue":"10193","key":"6593_CR14","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/S0140-6736(19)31149-3","volume":"394","author":"HC Gerstein","year":"2019","unstructured":"Gerstein HC, Colhoun HM, Dagenais GR et al (2019) Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet 394(10193):121\u2013130. https:\/\/doi.org\/10.1016\/S0140-6736(19)31149-3","journal-title":"Lancet"},{"issue":"9","key":"6593_CR15","doi-asserted-by":"publisher","first-page":"e12734","DOI":"10.1371\/journal.pone.0012734","volume":"5","author":"Q Wang","year":"2010","unstructured":"Wang Q, Chen K, Liu R et al (2010) Novel GLP-1 fusion chimera as potent long acting GLP-1 receptor agonist. PLoS One 5(9):e12734. https:\/\/doi.org\/10.1371\/journal.pone.0012734","journal-title":"PLoS One"},{"key":"6593_CR16","doi-asserted-by":"publisher","first-page":"930","DOI":"10.3389\/fphys.2019.00930","volume":"10","author":"L Ren","year":"2019","unstructured":"Ren L, Cui Q, Liu W et al (2019) Novel GLP-1 analog supaglutide stimulates insulin secretion in mouse and human islet beta-cells and improves glucose homeostasis in diabetic mice. Front Physiol 10:930. https:\/\/doi.org\/10.3389\/fphys.2019.00930","journal-title":"Front Physiol"},{"issue":"2","key":"6593_CR17","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1530\/JOE-20-0255","volume":"248","author":"Q Cui","year":"2021","unstructured":"Cui Q, Liao Y, Jiang Y et al (2021) Novel GLP-1 analog supaglutide improves glucose homeostasis in diabetic monkeys. J Endocrinol 248(2):145\u2013154. https:\/\/doi.org\/10.1530\/JOE-20-0255","journal-title":"J Endocrinol"},{"key":"6593_CR18","doi-asserted-by":"publisher","first-page":"294","DOI":"10.3389\/fphys.2017.00294","volume":"8","author":"Y Wan","year":"2017","unstructured":"Wan Y, Bao X, Huang J et al (2017) Novel GLP-1 analog supaglutide reduces HFD-induced obesity associated with increased Ucp-1 in white adipose tissue in mice. Front Physiol 8:294. https:\/\/doi.org\/10.3389\/fphys.2017.00294","journal-title":"Front Physiol"},{"issue":"8","key":"6593_CR19","doi-asserted-by":"publisher","first-page":"4220","DOI":"10.1111\/dom.16452","volume":"27","author":"Q Wang","year":"2025","unstructured":"Wang Q, Cui Q, Xu Y, Prud\u2019homme GJ (2025) Safety, pharmacokinetics and pharmacodynamics of efsubaglutide alfa in healthy participants: a randomized, dose-escalation phase 1 study. Diabetes Obes Metab 27(8):4220\u20134228. https:\/\/doi.org\/10.1111\/dom.16452","journal-title":"Diabetes Obes Metab"},{"key":"6593_CR20","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-025-01475-7","author":"YR Lou","year":"2025","unstructured":"Lou YR, Xu YL, Xiong Y, Deng C, Wang Q (2025) Population pharmacokinetics of efsubaglutide alfa in healthy subjects and subjects with type 2 diabetes. Clin Pharmacokinet. https:\/\/doi.org\/10.1007\/s40262-025-01475-7","journal-title":"Clin Pharmacokinet"},{"issue":"6","key":"6593_CR21","doi-asserted-by":"publisher","first-page":"1487","DOI":"10.2337\/diacare.27.6.1487","volume":"27","author":"TM Wallace","year":"2004","unstructured":"Wallace TM, Levy JC, Matthews DR (2004) Use and abuse of HOMA modeling. Diabetes Care 27(6):1487\u20131495. https:\/\/doi.org\/10.2337\/diacare.27.6.1487","journal-title":"Diabetes Care"},{"issue":"11","key":"6593_CR22","doi-asserted-by":"publisher","first-page":"1998","DOI":"10.1007\/s001250100003","volume":"44","author":"B Ahr\u00e9n","year":"2001","unstructured":"Ahr\u00e9n B, Larsson H (2001) Impaired glucose tolerance (IGT) is associated with reduced insulin-induced suppression of glucagon concentrations. Diabetologia 44(11):1998\u20132003. https:\/\/doi.org\/10.1007\/s001250100003","journal-title":"Diabetologia"},{"issue":"Suppl 1","key":"6593_CR23","doi-asserted-by":"publisher","first-page":"S212","DOI":"10.2337\/diabetes.51.2007.s212","volume":"51","author":"RN Bergman","year":"2002","unstructured":"Bergman RN, Ader M, Huecking K, Van Citters G (2002) Accurate assessment of beta-cell function: the hyperbolic correction. Diabetes 51(Suppl 1):S212-220. https:\/\/doi.org\/10.2337\/diabetes.51.2007.s212","journal-title":"Diabetes"},{"issue":"4","key":"6593_CR24","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/S2213-8587(17)30013-X","volume":"5","author":"C Sorli","year":"2017","unstructured":"Sorli C, Harashima SI, Tsoukas GM et al (2017) Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial. Lancet Diabetes Endocrinol 5(4):251\u2013260. https:\/\/doi.org\/10.1016\/S2213-8587(17)30013-X","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"8","key":"6593_CR25","doi-asserted-by":"publisher","first-page":"2168","DOI":"10.2337\/dc13-2759","volume":"37","author":"G Umpierrez","year":"2014","unstructured":"Umpierrez G, Tofe Povedano S, Perez Manghi F, Shurzinske L, Pechtner V (2014) Efficacy and safety of dulaglutide monotherapy versus metformin in type 2 diabetes in a randomized controlled trial (AWARD-3). Diabetes Care 37(8):2168\u20132176. https:\/\/doi.org\/10.2337\/dc13-2759","journal-title":"Diabetes Care"},{"issue":"10295","key":"6593_CR26","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/S0140-6736(21)01324-6","volume":"398","author":"J Rosenstock","year":"2021","unstructured":"Rosenstock J, Wysham C, Frias JP et al (2021) Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial. Lancet 398(10295):143\u2013155. https:\/\/doi.org\/10.1016\/S0140-6736(21)01324-6","journal-title":"Lancet"},{"issue":"1","key":"6593_CR27","doi-asserted-by":"publisher","first-page":"128","DOI":"10.2337\/db21-0416","volume":"71","author":"E Vazquez Arreola","year":"2021","unstructured":"Vazquez Arreola E, Hanson RL, Bogardus C, Knowler WC (2021) Relationship between insulin secretion and insulin sensitivity and its role in development of type 2 diabetes mellitus: beyond the disposition index. Diabetes 71(1):128\u2013141. https:\/\/doi.org\/10.2337\/db21-0416","journal-title":"Diabetes"},{"issue":"9","key":"6593_CR28","doi-asserted-by":"publisher","first-page":"2121","DOI":"10.1111\/dom.13340","volume":"20","author":"YH Chen","year":"2018","unstructured":"Chen YH, Huang CN, Cho YM et al (2018) Efficacy and safety of dulaglutide monotherapy compared with glimepiride in East-Asian patients with type 2 diabetes in a multicentre, double-blind, randomized, parallel-arm, active comparator, phase III trial. Diabetes Obes Metab 20(9):2121\u20132130. https:\/\/doi.org\/10.1111\/dom.13340","journal-title":"Diabetes Obes Metab"},{"issue":"2","key":"6593_CR29","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1111\/dom.13082","volume":"20","author":"Y Seino","year":"2018","unstructured":"Seino Y, Terauchi Y, Osonoi T et al (2018) Safety and efficacy of semaglutide once weekly vs sitagliptin once daily, both as monotherapy in Japanese people with type 2 diabetes. Diabetes Obes Metab 20(2):378\u2013388. https:\/\/doi.org\/10.1111\/dom.13082","journal-title":"Diabetes Obes Metab"},{"issue":"5","key":"6593_CR30","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1016\/s2213-8587(17)30092-x","volume":"5","author":"B Ahr\u00e9n","year":"2017","unstructured":"Ahr\u00e9n B, Masmiquel L, Kumar H et al (2017) Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as an add-on to metformin, thiazolidinediones, or both, in patients with type 2 diabetes (SUSTAIN 2): a 56-week, double-blind, phase 3a, randomised trial. Lancet Diabetes Endocrinol 5(5):341\u2013354. https:\/\/doi.org\/10.1016\/s2213-8587(17)30092-x","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"10","key":"6593_CR31","doi-asserted-by":"publisher","first-page":"2242","DOI":"10.1111\/dom.14465","volume":"23","author":"E Bonora","year":"2021","unstructured":"Bonora E, Frias JP, Tinahones FJ et al (2021) Effect of dulaglutide 3.0 and 4.5 mg on weight in patients with type 2 diabetes: exploratory analyses of AWARD-11. Diabetes Obes Metab 23(10):2242\u20132250. https:\/\/doi.org\/10.1111\/dom.14465","journal-title":"Diabetes Obes Metab"},{"issue":"1","key":"6593_CR32","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1186\/s12877-022-02979-8","volume":"22","author":"QSJ Zhou","year":"2022","unstructured":"Zhou QSJ, Wu Z et al (2022) The older, the less potential benefit for type 2 diabetes from weight control. BMC Geriatr 22(1):346. https:\/\/doi.org\/10.1186\/s12877-022-02979-8","journal-title":"BMC Geriatr"},{"issue":"Supplement_1","key":"6593_CR33","doi-asserted-by":"publisher","first-page":"738-P","DOI":"10.2337\/db25-738-P","volume":"74","author":"Y Bao","year":"2025","unstructured":"Bao Y, Zhou J, Gao F et al (2025) 738-P: efficacy and safety of efsubaglutide alfa in patients with obesity or overweight\u2014a phase 2 study. Diabetes 74(Supplement_1):738-P. https:\/\/doi.org\/10.2337\/db25-738-P","journal-title":"Diabetes"},{"issue":"1","key":"6593_CR34","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1111\/dom.15309","volume":"26","author":"L Ji","year":"2024","unstructured":"Ji L, Ahmann AJ, Ahr\u00e9n B et al (2024) Proportion of participants with type 2 diabetes achieving a metabolic composite endpoint with once-weekly semaglutide treatment versus comparators: post hoc pooled analysis from SUSTAIN 1\u20135, 7\u201310 and SUSTAIN China. Diabetes Obes Metab 26(1):233\u2013241. https:\/\/doi.org\/10.1111\/dom.15309","journal-title":"Diabetes Obes Metab"},{"key":"6593_CR35","doi-asserted-by":"publisher","first-page":"645563","DOI":"10.3389\/fendo.2021.645563","volume":"12","author":"MM Smits","year":"2021","unstructured":"Smits MM, Van Raalte DH (2021) Safety of semaglutide. Front Endocrinol (Lausanne) 12:645563. https:\/\/doi.org\/10.3389\/fendo.2021.645563","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"10","key":"6593_CR36","doi-asserted-by":"publisher","first-page":"2783","DOI":"10.1007\/s13300-021-01140-9","volume":"12","author":"J Van","year":"2021","unstructured":"Van J, Frias JP, Bonora E et al (2021) Gastrointestinal tolerability of once-weekly dulaglutide 3.0 mg and 4.5 mg: a post hoc analysis of the incidence and prevalence of nausea, vomiting, and diarrhea in AWARD-11. Diabetes Ther 12(10):2783\u20132794. https:\/\/doi.org\/10.1007\/s13300-021-01140-9","journal-title":"Diabetes Ther"},{"issue":"6","key":"6593_CR37","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1056\/NEJMoa2107519","volume":"385","author":"JP Frias","year":"2021","unstructured":"Frias JP, Davies MJ, Rosenstock J et al (2021) Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. N Engl J Med 385(6):503\u2013515. https:\/\/doi.org\/10.1056\/NEJMoa2107519","journal-title":"N Engl J Med"},{"issue":"6","key":"6593_CR38","doi-asserted-by":"publisher","first-page":"1500","DOI":"10.1038\/s41591-023-02344-1","volume":"29","author":"L Gao","year":"2023","unstructured":"Gao L, Lee BW, Chawla M et al (2023) Tirzepatide versus insulin glargine as second-line or third-line therapy in type 2 diabetes in the Asia-Pacific region: the SURPASS-AP-Combo trial. Nat Med 29(6):1500\u20131510. https:\/\/doi.org\/10.1038\/s41591-023-02344-1","journal-title":"Nat Med"}],"updated-by":[{"DOI":"10.1007\/s00125-026-06711-8","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T00:00:00Z","timestamp":1773878400000}}],"container-title":["Diabetologia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00125-025-06593-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00125-025-06593-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00125-025-06593-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T11:08:06Z","timestamp":1777028886000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00125-025-06593-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,21]]},"references-count":38,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["6593"],"URL":"https:\/\/doi.org\/10.1007\/s00125-025-06593-2","relation":{},"ISSN":["0012-186X","1432-0428"],"issn-type":[{"value":"0012-186X","type":"print"},{"value":"1432-0428","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,21]]},"assertion":[{"value":"1 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 March 2026","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The original online version of this article was revised: Fig. 2d was corrected.","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 March 2026","order":8,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":9,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":10,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s00125-026-06711-8","URL":"https:\/\/doi.org\/10.1007\/s00125-026-06711-8","order":11,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"We thank N. Zhao (Fudan University) for his contribution to the statistical analysis plan and strategy. We thank all the clinical trial participants for their participation, and all the investigators and their trial-site support staff who generously participated in this work. We thank C. Peng for his editorial assistance with the submitted version of the manuscript.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Acknowledgements"}},{"value":"All data are available from the corresponding author (QW), upon reasonable request.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data availability"}},{"value":"This study was sponsored by Innogen Pharmaceutical Co. Ltd. The study sponsor provided the study drugs and was involved in the study design, data collection, data review, data analysis, and drafting of this manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"QW is the founder of Innogen Pharmaceutical Co. Ltd, and YX is an employee of the company. The remaining authors declare that there are no relationships or activities that might bias, or be perceived to bias, their work.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 relationships and activities"}},{"value":"All authors contributed to the design of the trial and participated in the conduct of the trial and data collection. WW, YX, QW and DZ took part in the data analysis. All authors interpreted the data and participated in writing the manuscript. All authors read and approved the submitted version of the manuscript. All authors had full access to all the data in the study and had final responsibility for the decision to submit for publication. QW is the guarantor of this work.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Contribution statement"}}]}}